Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 40 | 2021 | 638 | 7.140 |
Why?
|
Glioblastoma | 29 | 2020 | 157 | 6.120 |
Why?
|
Receptor, EphA2 | 9 | 2021 | 13 | 2.970 |
Why?
|
Ephrin-A1 | 8 | 2017 | 11 | 2.730 |
Why?
|
Glioma | 13 | 2021 | 136 | 2.650 |
Why?
|
Interleukin-13 Receptor alpha2 Subunit | 8 | 2017 | 11 | 1.950 |
Why?
|
Drug Delivery Systems | 8 | 2021 | 101 | 1.840 |
Why?
|
Antineoplastic Agents | 10 | 2020 | 611 | 1.760 |
Why?
|
Neoplasms | 9 | 2018 | 695 | 1.470 |
Why?
|
Interleukin-13 | 9 | 2012 | 33 | 1.260 |
Why?
|
Cell Line, Tumor | 23 | 2020 | 736 | 1.170 |
Why?
|
Cytotoxins | 5 | 2021 | 13 | 1.160 |
Why?
|
Immunotoxins | 5 | 2016 | 17 | 1.030 |
Why?
|
Signal Transduction | 4 | 2014 | 701 | 0.980 |
Why?
|
Proto-Oncogene Proteins c-fos | 3 | 2011 | 9 | 0.950 |
Why?
|
Astrocytoma | 4 | 2018 | 29 | 0.880 |
Why?
|
Peptides | 5 | 2017 | 120 | 0.870 |
Why?
|
Humans | 63 | 2020 | 32297 | 0.850 |
Why?
|
Receptors, Eph Family | 2 | 2014 | 2 | 0.840 |
Why?
|
Bacterial Toxins | 5 | 2013 | 16 | 0.790 |
Why?
|
Receptors, Interleukin | 5 | 2004 | 16 | 0.790 |
Why?
|
Animals | 29 | 2021 | 7694 | 0.750 |
Why?
|
Immunotherapy | 3 | 2020 | 83 | 0.740 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2019 | 262 | 0.660 |
Why?
|
Blood-Brain Barrier | 3 | 2020 | 50 | 0.660 |
Why?
|
Convection | 3 | 2021 | 8 | 0.640 |
Why?
|
Binding Sites | 7 | 2013 | 132 | 0.630 |
Why?
|
Protein Binding | 7 | 2016 | 206 | 0.600 |
Why?
|
Cancer Vaccines | 2 | 2008 | 24 | 0.580 |
Why?
|
Ephrin-A5 | 1 | 2016 | 2 | 0.570 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2016 | 18 | 0.560 |
Why?
|
Cell Proliferation | 9 | 2020 | 602 | 0.550 |
Why?
|
Mice | 16 | 2020 | 2524 | 0.540 |
Why?
|
Ephrins | 1 | 2014 | 1 | 0.500 |
Why?
|
Blotting, Western | 7 | 2013 | 305 | 0.500 |
Why?
|
Ligands | 6 | 2013 | 89 | 0.500 |
Why?
|
Brain | 4 | 2018 | 971 | 0.490 |
Why?
|
Mice, Nude | 10 | 2020 | 298 | 0.470 |
Why?
|
Polymers | 1 | 2013 | 60 | 0.450 |
Why?
|
Tumor Cells, Cultured | 5 | 2016 | 171 | 0.450 |
Why?
|
Matrix Metalloproteinases | 1 | 2012 | 10 | 0.420 |
Why?
|
Antibodies, Monoclonal | 2 | 2013 | 250 | 0.420 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 85 | 0.410 |
Why?
|
Peptide Library | 1 | 2011 | 6 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2011 | 7 | 0.390 |
Why?
|
Genetic Vectors | 2 | 2010 | 125 | 0.380 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 119 | 0.380 |
Why?
|
Apoptosis | 4 | 2016 | 368 | 0.380 |
Why?
|
Molecular Sequence Data | 5 | 2013 | 359 | 0.370 |
Why?
|
Cell Movement | 5 | 2020 | 171 | 0.370 |
Why?
|
Interleukin-13 Receptor alpha1 Subunit | 6 | 2012 | 10 | 0.350 |
Why?
|
Anticonvulsants | 1 | 2009 | 69 | 0.340 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2020 | 46 | 0.340 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 502 | 0.330 |
Why?
|
Dogs | 3 | 2021 | 129 | 0.330 |
Why?
|
Diphtheria Toxin | 1 | 2009 | 23 | 0.330 |
Why?
|
Vaccines, DNA | 1 | 2008 | 4 | 0.330 |
Why?
|
Immunotherapy, Active | 1 | 2008 | 6 | 0.330 |
Why?
|
Transcription Factors | 3 | 2019 | 181 | 0.330 |
Why?
|
Cell Hypoxia | 1 | 2009 | 41 | 0.330 |
Why?
|
Photosensitizing Agents | 2 | 2018 | 23 | 0.320 |
Why?
|
Genomics | 3 | 2018 | 85 | 0.320 |
Why?
|
Alanine | 2 | 2012 | 27 | 0.320 |
Why?
|
Amino Acid Sequence | 4 | 2013 | 287 | 0.320 |
Why?
|
Mutation | 6 | 2013 | 503 | 0.310 |
Why?
|
Oxygen | 1 | 2009 | 142 | 0.310 |
Why?
|
Neoplastic Stem Cells | 2 | 2019 | 99 | 0.310 |
Why?
|
Recombinant Proteins | 5 | 2012 | 258 | 0.310 |
Why?
|
Transfection | 5 | 2015 | 202 | 0.290 |
Why?
|
Exotoxins | 4 | 2013 | 9 | 0.280 |
Why?
|
MicroRNAs | 2 | 2018 | 180 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 462 | 0.240 |
Why?
|
Transgenes | 4 | 2011 | 48 | 0.240 |
Why?
|
Receptors, Interleukin-13 | 5 | 2004 | 9 | 0.240 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2018 | 58 | 0.240 |
Why?
|
Radiosurgery | 2 | 2019 | 356 | 0.230 |
Why?
|
Immunization, Passive | 1 | 2003 | 9 | 0.230 |
Why?
|
Sulfones | 2 | 2020 | 21 | 0.230 |
Why?
|
Indans | 2 | 2020 | 31 | 0.220 |
Why?
|
Surface Plasmon Resonance | 2 | 2013 | 7 | 0.220 |
Why?
|
Protein Structure, Secondary | 3 | 2012 | 47 | 0.210 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2013 | 71 | 0.210 |
Why?
|
Recombinant Fusion Proteins | 2 | 2013 | 103 | 0.210 |
Why?
|
Binding, Competitive | 2 | 2013 | 37 | 0.210 |
Why?
|
Protein Structure, Tertiary | 2 | 2013 | 102 | 0.210 |
Why?
|
Up-Regulation | 3 | 2018 | 196 | 0.200 |
Why?
|
Photochemotherapy | 2 | 2018 | 21 | 0.200 |
Why?
|
ADP Ribose Transferases | 2 | 2013 | 3 | 0.190 |
Why?
|
Virulence Factors | 2 | 2013 | 9 | 0.190 |
Why?
|
Electromagnetic Fields | 2 | 2018 | 26 | 0.190 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2018 | 40 | 0.190 |
Why?
|
Radiotherapy | 2 | 2018 | 82 | 0.190 |
Why?
|
Female | 17 | 2019 | 20126 | 0.180 |
Why?
|
Ephrin-A2 | 2 | 2013 | 2 | 0.180 |
Why?
|
Breast Neoplasms | 3 | 2019 | 759 | 0.180 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2013 | 39 | 0.170 |
Why?
|
Syndecan-1 | 1 | 2019 | 11 | 0.170 |
Why?
|
Plasma Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
Single-Chain Antibodies | 2 | 2016 | 3 | 0.170 |
Why?
|
Cells, Cultured | 2 | 2013 | 846 | 0.160 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 167 | 0.160 |
Why?
|
Flow Cytometry | 2 | 2013 | 187 | 0.160 |
Why?
|
Immunoconjugates | 1 | 2018 | 9 | 0.160 |
Why?
|
Neovascularization, Pathologic | 3 | 2016 | 82 | 0.160 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 20 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.160 |
Why?
|
Microfilament Proteins | 1 | 2018 | 35 | 0.160 |
Why?
|
Gene Silencing | 2 | 2011 | 49 | 0.160 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 316 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 105 | 0.160 |
Why?
|
Immunohistochemistry | 3 | 2015 | 545 | 0.150 |
Why?
|
Microglia | 1 | 2018 | 58 | 0.150 |
Why?
|
DNA Damage | 1 | 2018 | 100 | 0.150 |
Why?
|
Exosomes | 1 | 2018 | 43 | 0.150 |
Why?
|
Electroporation | 1 | 2017 | 14 | 0.150 |
Why?
|
Alpha Particles | 1 | 2017 | 7 | 0.150 |
Why?
|
Male | 15 | 2019 | 19488 | 0.150 |
Why?
|
Bone Neoplasms | 1 | 2018 | 112 | 0.140 |
Why?
|
Receptors, Cell Surface | 2 | 2015 | 73 | 0.140 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2016 | 244 | 0.140 |
Why?
|
Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.140 |
Why?
|
Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2016 | 2 | 0.140 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2016 | 77 | 0.140 |
Why?
|
Circular Dichroism | 3 | 2012 | 30 | 0.140 |
Why?
|
Mutagenesis, Site-Directed | 3 | 2012 | 64 | 0.140 |
Why?
|
Fluorodeoxyuridylate | 1 | 2016 | 23 | 0.140 |
Why?
|
CHO Cells | 2 | 2008 | 27 | 0.140 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 55 | 0.140 |
Why?
|
Cricetinae | 2 | 2008 | 64 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2015 | 3 | 0.130 |
Why?
|
Prostatic Neoplasms | 2 | 2013 | 492 | 0.130 |
Why?
|
RNA, Small Interfering | 2 | 2018 | 117 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 101 | 0.130 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 149 | 0.120 |
Why?
|
Cell Survival | 2 | 2007 | 301 | 0.120 |
Why?
|
DNA Primers | 3 | 2002 | 90 | 0.120 |
Why?
|
Recurrence | 2 | 2019 | 266 | 0.120 |
Why?
|
Caspases | 1 | 2013 | 42 | 0.120 |
Why?
|
Dog Diseases | 1 | 2013 | 8 | 0.120 |
Why?
|
Triazines | 1 | 2013 | 3 | 0.120 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2013 | 7 | 0.120 |
Why?
|
Immunoprecipitation | 1 | 2013 | 34 | 0.120 |
Why?
|
Middle Aged | 10 | 2019 | 11949 | 0.120 |
Why?
|
Antigens, Surface | 1 | 2013 | 25 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2013 | 49 | 0.110 |
Why?
|
Fluorouracil | 1 | 2013 | 82 | 0.110 |
Why?
|
Glycosylation | 1 | 2013 | 15 | 0.110 |
Why?
|
Protein Multimerization | 1 | 2013 | 22 | 0.110 |
Why?
|
Crystallography, X-Ray | 1 | 2013 | 92 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 264 | 0.110 |
Why?
|
Trans-Activators | 2 | 2011 | 46 | 0.110 |
Why?
|
DNA Methylation | 3 | 2015 | 142 | 0.110 |
Why?
|
Radioisotopes | 1 | 2012 | 5 | 0.110 |
Why?
|
Mice, Inbred BALB C | 3 | 2018 | 171 | 0.110 |
Why?
|
Models, Molecular | 1 | 2013 | 197 | 0.110 |
Why?
|
Protein Engineering | 1 | 2012 | 19 | 0.110 |
Why?
|
Phosphoinositide Phospholipase C | 1 | 2012 | 3 | 0.110 |
Why?
|
Cerebral Cortex | 1 | 2013 | 137 | 0.110 |
Why?
|
Drug Carriers | 1 | 2012 | 20 | 0.110 |
Why?
|
Cytoplasm | 1 | 2012 | 34 | 0.110 |
Why?
|
Culture Media, Conditioned | 1 | 2012 | 52 | 0.100 |
Why?
|
Mutagenesis | 1 | 2012 | 33 | 0.100 |
Why?
|
Transcriptional Activation | 2 | 2018 | 43 | 0.100 |
Why?
|
Time Factors | 2 | 2016 | 2181 | 0.100 |
Why?
|
Protein Conformation | 1 | 2012 | 89 | 0.100 |
Why?
|
Protein Isoforms | 1 | 2012 | 58 | 0.100 |
Why?
|
Mass Spectrometry | 1 | 2012 | 105 | 0.100 |
Why?
|
Cell Physiological Phenomena | 1 | 2011 | 3 | 0.100 |
Why?
|
Cytoskeleton | 1 | 2011 | 19 | 0.100 |
Why?
|
rho GTP-Binding Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
Treatment Outcome | 4 | 2015 | 3358 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 675 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 105 | 0.100 |
Why?
|
Lung Neoplasms | 1 | 2016 | 409 | 0.100 |
Why?
|
Cell Membrane | 1 | 2012 | 103 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2012 | 112 | 0.100 |
Why?
|
Adult | 8 | 2019 | 9467 | 0.100 |
Why?
|
Models, Biological | 2 | 2017 | 397 | 0.100 |
Why?
|
Viruses | 1 | 2010 | 3 | 0.100 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 77 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2018 | 4050 | 0.090 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 2 | 2007 | 6 | 0.090 |
Why?
|
Gene Expression | 2 | 2017 | 345 | 0.090 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 410 | 0.090 |
Why?
|
Cyclooxygenase 2 | 2 | 2007 | 46 | 0.090 |
Why?
|
Gene Transfer Techniques | 1 | 2010 | 72 | 0.090 |
Why?
|
Endothelial Cells | 1 | 2011 | 187 | 0.090 |
Why?
|
Disease Progression | 3 | 2018 | 618 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2015 | 196 | 0.090 |
Why?
|
Neurons | 1 | 2013 | 413 | 0.090 |
Why?
|
Aged | 7 | 2018 | 10398 | 0.090 |
Why?
|
Catheters, Indwelling | 1 | 2009 | 42 | 0.090 |
Why?
|
Furin | 1 | 2009 | 3 | 0.080 |
Why?
|
Cell Line | 2 | 2007 | 462 | 0.080 |
Why?
|
Cricetulus | 1 | 2008 | 17 | 0.080 |
Why?
|
Autoradiography | 1 | 2008 | 47 | 0.080 |
Why?
|
Young Adult | 4 | 2018 | 2626 | 0.080 |
Why?
|
Pseudomonas | 2 | 2010 | 6 | 0.080 |
Why?
|
Astrocytes | 2 | 2019 | 58 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2018 | 3514 | 0.080 |
Why?
|
Tissue Array Analysis | 1 | 2008 | 34 | 0.080 |
Why?
|
Adolescent | 4 | 2018 | 3571 | 0.080 |
Why?
|
Follow-Up Studies | 3 | 2018 | 2296 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 894 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2005 | 2 | 0.070 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 5 | 0.070 |
Why?
|
Fluorescent Antibody Technique | 1 | 2005 | 94 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2005 | 36 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 567 | 0.060 |
Why?
|
Transcription Factor AP-1 | 1 | 2005 | 19 | 0.060 |
Why?
|
Base Sequence | 2 | 2002 | 257 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 57 | 0.060 |
Why?
|
Dacarbazine | 2 | 2016 | 29 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 163 | 0.060 |
Why?
|
Cell Division | 1 | 2005 | 98 | 0.060 |
Why?
|
Cell Adhesion | 1 | 2005 | 107 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2015 | 78 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2015 | 320 | 0.060 |
Why?
|
Protein Structure, Quaternary | 1 | 2004 | 18 | 0.060 |
Why?
|
Prognosis | 2 | 2018 | 1523 | 0.060 |
Why?
|
Genotype | 1 | 2005 | 742 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2003 | 12 | 0.060 |
Why?
|
RNA, Messenger | 1 | 2005 | 534 | 0.060 |
Why?
|
Phenotype | 1 | 2005 | 656 | 0.050 |
Why?
|
Receptors, Virus | 1 | 2002 | 15 | 0.050 |
Why?
|
Herpesvirus 1, Human | 1 | 2002 | 7 | 0.050 |
Why?
|
Antibody Formation | 1 | 2003 | 51 | 0.050 |
Why?
|
DNA, Antisense | 1 | 2002 | 1 | 0.050 |
Why?
|
Viral Envelope Proteins | 1 | 2002 | 17 | 0.050 |
Why?
|
Blotting, Northern | 1 | 2002 | 31 | 0.050 |
Why?
|
Dimerization | 1 | 2002 | 24 | 0.050 |
Why?
|
Interleukin-4 | 1 | 2002 | 22 | 0.050 |
Why?
|
Cloning, Molecular | 1 | 2002 | 76 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 190 | 0.050 |
Why?
|
Escherichia coli | 1 | 2002 | 87 | 0.050 |
Why?
|
Receptors, Transferrin | 1 | 2002 | 10 | 0.050 |
Why?
|
RNA | 1 | 2002 | 95 | 0.050 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 190 | 0.050 |
Why?
|
Asthma | 1 | 2005 | 438 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2003 | 773 | 0.050 |
Why?
|
Proteins | 1 | 2002 | 150 | 0.050 |
Why?
|
Cohort Studies | 2 | 2015 | 1832 | 0.050 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 65 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 172 | 0.040 |
Why?
|
Nanomedicine | 1 | 2018 | 18 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 66 | 0.040 |
Why?
|
Infrared Rays | 1 | 2018 | 18 | 0.040 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2018 | 13 | 0.040 |
Why?
|
Doxorubicin | 1 | 2018 | 79 | 0.040 |
Why?
|
RNA Interference | 1 | 2018 | 77 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
Down-Regulation | 1 | 2018 | 144 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2018 | 123 | 0.040 |
Why?
|
Cysteamine | 1 | 2017 | 2 | 0.040 |
Why?
|
Actinium | 1 | 2017 | 3 | 0.040 |
Why?
|
Copper Radioisotopes | 1 | 2017 | 3 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 1345 | 0.040 |
Why?
|
Cell Size | 1 | 2017 | 38 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2017 | 17 | 0.040 |
Why?
|
Isotope Labeling | 1 | 2017 | 17 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2018 | 261 | 0.040 |
Why?
|
X-Ray Microtomography | 1 | 2017 | 40 | 0.040 |
Why?
|
Cell Death | 1 | 2017 | 77 | 0.040 |
Why?
|
Membrane Potentials | 1 | 2017 | 81 | 0.040 |
Why?
|
Coculture Techniques | 1 | 2017 | 81 | 0.040 |
Why?
|
Finite Element Analysis | 1 | 2017 | 81 | 0.040 |
Why?
|
Hydrogels | 1 | 2017 | 122 | 0.030 |
Why?
|
Collagen | 1 | 2017 | 228 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2015 | 16 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 72 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2015 | 134 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 222 | 0.030 |
Why?
|
Survival Analysis | 1 | 2015 | 491 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2007 | 911 | 0.030 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 34 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2013 | 8 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 171 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 82 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 2013 | 30 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2017 | 1040 | 0.030 |
Why?
|
Rats | 1 | 2017 | 1675 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2007 | 849 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 2012 | 8 | 0.030 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2012 | 19 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 54 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2007 | 1092 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 986 | 0.020 |
Why?
|
Immunocompetence | 1 | 2010 | 12 | 0.020 |
Why?
|
Neurotoxins | 1 | 2010 | 16 | 0.020 |
Why?
|
Adenoviridae | 1 | 2010 | 66 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 920 | 0.020 |
Why?
|
Europe | 1 | 2007 | 83 | 0.020 |
Why?
|
Hypersensitivity | 1 | 2007 | 27 | 0.020 |
Why?
|
Haplotypes | 1 | 2007 | 224 | 0.020 |
Why?
|
STAT6 Transcription Factor | 1 | 2005 | 1 | 0.020 |
Why?
|
ADAM Proteins | 1 | 2005 | 13 | 0.020 |
Why?
|
Metalloendopeptidases | 1 | 2005 | 11 | 0.020 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 149 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2005 | 260 | 0.010 |
Why?
|
Hemagglutinins, Viral | 1 | 2002 | 1 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2002 | 23 | 0.010 |
Why?
|
Genome, Viral | 1 | 2002 | 11 | 0.010 |
Why?
|
Open Reading Frames | 1 | 2002 | 20 | 0.010 |
Why?
|
Virus Replication | 1 | 2002 | 52 | 0.010 |
Why?
|